AstraZeneca's upset stomach: AstraZeneca delayed entry of generic competitors of its anti-ulcer drug and
prevented parallel trade by
abusing patents and marketing procedures, the European Court of Justice held in reducing AstraZeneca's fine slightly, to $ 52.5 million from $ 60 million.